CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
40.72 EUR
+0.42 (+1.04%)
We assign a fundamental rating of 5 out of 10 to AFX. AFX was compared to 62 industry peers in the Health Care Equipment & Supplies industry. AFX has only an average score on both its financial health and profitability. AFX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
AFX had positive earnings in the past year.
In the past year AFX had a positive cash flow from operations.
AFX had positive earnings in each of the past 5 years.
In the past 5 years AFX always reported a positive cash flow from operatings.
1.2 Ratios
AFX has a Return On Assets of 4.15%. This is in the better half of the industry: AFX outperforms 62.90% of its industry peers.
Looking at the Return On Equity, with a value of 6.67%, AFX is in line with its industry, outperforming 53.23% of the companies in the same industry.
AFX has a Return On Invested Capital of 5.79%. This is comparable to the rest of the industry: AFX outperforms 54.84% of its industry peers.
AFX had an Average Return On Invested Capital over the past 3 years of 7.11%. This is below the industry average of 9.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
AFX's Profit Margin of 6.34% is in line compared to the rest of the industry. AFX outperforms 54.84% of its industry peers.
In the last couple of years the Profit Margin of AFX has declined.
AFX has a Operating Margin (10.03%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of AFX has declined.
With a Gross Margin value of 52.76%, AFX perfoms like the industry average, outperforming 43.55% of the companies in the same industry.
In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
AFX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AFX has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, AFX has less shares outstanding
AFX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.46 indicates that AFX is not in any danger for bankruptcy at the moment.
The Altman-Z score of AFX (3.46) is better than 64.52% of its industry peers.
The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of AFX (4.41) is comparable to the rest of the industry.
AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AFX (0.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 3.46 |
ROIC/WACC0.86
WACC6.73%
2.3 Liquidity
AFX has a Current Ratio of 2.35. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.35, AFX is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
A Quick Ratio of 1.44 indicates that AFX should not have too much problems paying its short term obligations.
AFX has a better Quick ratio (1.44) than 70.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for AFX have decreased strongly by -19.90% in the last year.
The Earnings Per Share has been growing slightly by 3.28% on average over the past years.
The Revenue has been growing slightly by 7.82% in the past year.
AFX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.78% yearly.
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
3.2 Future
The Earnings Per Share is expected to grow by 20.13% on average over the next years. This is a very strong growth
Based on estimates for the next years, AFX will show a small growth in Revenue. The Revenue will grow by 6.98% on average per year.
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y20.13%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.98%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 25.29 indicates a quite expensive valuation of AFX.
Based on the Price/Earnings ratio, AFX is valued a bit cheaper than 67.74% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.84. AFX is around the same levels.
With a Price/Forward Earnings ratio of 20.32, AFX is valued on the expensive side.
AFX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AFX is cheaper than 62.90% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.40. AFX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.29 | ||
| Fwd PE | 20.32 |
4.2 Price Multiples
AFX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AFX is cheaper than 75.81% of the companies in the same industry.
AFX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AFX is cheaper than 69.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.33 | ||
| EV/EBITDA | 11.77 |
4.3 Compensation for Growth
AFX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as AFX's earnings are expected to grow with 22.65% in the coming years.
PEG (NY)1.03
PEG (5Y)7.71
EPS Next 2Y22.06%
EPS Next 3Y22.65%
5. Dividend
5.1 Amount
AFX has a Yearly Dividend Yield of 1.36%.
AFX's Dividend Yield is a higher than the industry average which is at 1.11.
Compared to the average S&P500 Dividend Yield of 2.00, AFX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.36% |
5.2 History
The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
37.19% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
DP37.19%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
FRA:AFX (12/29/2025, 5:35:30 PM)
40.72
+0.42 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.64B
Revenue(TTM)2.23B
Net Income(TTM)141.22M
Analysts73.64
Price Target51.15 (25.61%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.36% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.94%
PT rev (3m)-7.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.17%
EPS NY rev (3m)-6.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.69%
Revenue NY rev (3m)-0.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.29 | ||
| Fwd PE | 20.32 | ||
| P/S | 1.63 | ||
| P/FCF | 27.33 | ||
| P/OCF | 17.35 | ||
| P/B | 1.72 | ||
| P/tB | 7.53 | ||
| EV/EBITDA | 11.77 |
EPS(TTM)1.61
EY3.95%
EPS(NY)2
Fwd EY4.92%
FCF(TTM)1.49
FCFY3.66%
OCF(TTM)2.35
OCFY5.76%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)1.03
PEG (5Y)7.71
Graham Number29.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 3.46 |
F-Score6
WACC6.73%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y20.13%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.98%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year66.85%
EBIT Next 3Y28.21%
EBIT Next 5Y23.57%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?
ChartMill assigns a valuation rating of 4 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 25.29 and the Price/Book (PB) ratio is 1.72.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.